SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is currently a major focus of community debate, with investors weighing the potential for ecosystem-wide utility and token burns against frustrations over its extended price stagnation. While some traders continue to advocate for the token's long-term potential as a blockchain project, others are actively criticizing its performance and movement, leading to a polarized environment across social forums.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing significant downward pressure as the community expresses extreme frustration over continuous price declines and a perceived lack of support. While some investors argue that the token's current valuation is a deep-value opportunity based on its enterprise partnerships and real-world utility, many others are debating whether the asset has become a value trap or if it is undergoing a final capitulation phase.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Georgetown, TX.

TSS Inc

TSSI is trending as investors debate whether the company is a high-margin AI infrastructure player or a limited service provider following a significant revenue miss that overshadowed steady growth in its systems integration business. The community is sharply divided, with bulls pointing to the company's deepening ties with Dell and expanded capacity as key catalysts for a long-term turnaround, while bears are highlighting lackluster quarterly revenue figures and persistent insider selling as signals of deeper operational weakness.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending as investors react to the company reaching an agreement with the FDA on a path to resubmit its BLA for RP1, following previous regulatory setbacks. The community remains deeply divided, with bulls pointing to the renewed regulatory pathway as a potential turnaround, while bears continue to highlight financial risks, staff reductions, and unresolved concerns over trial design and product efficacy.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is facing significant price volatility and community debate following the departure of a major subnet operator, which has intensified concerns over network centralization. While some investors view the pullback as a buying opportunity in a long-term AI-infrastructure play, others remain cautious as they weigh technical governance concerns against the project's long-term utility.

Anthropic

Anthropic is currently a focal point of market discussion as it scales compute-heavy infrastructure through multi-billion dollar deals and prepares for a highly anticipated IPO. The community is actively debating the company's competitive standing against industry peers like OpenAI, its complex web of strategic partnerships, and the ongoing scrutiny surrounding AI safety and sovereign regulation.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is gaining significant community attention as investors anticipate the impact of upcoming partnerships and infrastructure developments, including real-world asset tokenization and payment rail integrations. Supporters view current price levels as a generational accumulation opportunity, highlighting the project's utility and long-term potential compared to established crypto assets.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Forgent Power Solutions is seeing heavy volatility as investors weigh the company's aggressive backlog growth and AI-driven power infrastructure demand against concerns over recent secondary offerings and shareholder dilution. While some in the community remain bullish on the long-term potential of the firm's utility-critical hardware, others are expressing frustration over management's capital structure and frequent equity supply increases.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group remains a high-beta battleground as retail traders debate the potential for a second short squeeze, fueled by tight float concerns and lingering memories of its previous parabolic run. Market participants are split between those betting on continued volatility and those emphasizing the company's significant debt load as a long-term fundamental headwind.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devon Energy is trending as investors weigh the strategic implications of its landmark merger with Coterra Energy alongside escalating geopolitical tensions in the Middle East affecting oil shipping lanes. Community discussion is heavily focused on the company's path toward operational efficiency, boosted shareholder returns through dividend hikes and share buybacks, and its potential as a core defensive holding in an increasingly volatile energy market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lilly’s Phase 3 Breakthrough Ignites Race for the Next Cancer Stock Breakout

Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. $LLY, $NTHI, $COGT, $OLMA, $BMY, $PFE

Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study

Equity

Early ASCO data for OP-3136 pointed to encouraging anti-cancer activity with a clean safety profile, adding momentum to OLMA’s pipeline story.

Olema Pharmaceuticals (OLMA) Expected to Announce Quarterly Earnings on Tuesday

Olema Pharmaceuticals (NASDAQ:OLMA) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-olema-pharmaceuticals-inc-stock...

Jennison Associates LLC Takes Position in Olema Pharmaceuticals, Inc. $OLMA

Jennison Associates LLC purchased a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 963,997 shares of the company's stock, valued at approximatel...

Pictet Asset Management Holding SA Trims Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA

Pictet Asset Management Holding SA lessened its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 69.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 502,568...

Wall Street Zen Upgrades Olema Pharmaceuticals (NASDAQ:OLMA) to "Sell"

Wall Street Zen raised Olema Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Monday...

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen brokerages that are covering the company, Marketbeat...

Olema Pharmaceuticals (NASDAQ:OLMA) Downgraded to "Strong Sell" Rating by Wall Street Zen

Wall Street Zen downgraded shares of Olema Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Sunday...

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Short Interest Update

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling...

Olema Pharmaceuticals (NASDAQ:OLMA) Raised to "Sell" at Wall Street Zen

Wall Street Zen upgraded shares of Olema Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Saturday...

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Olema Pharmaceuticals Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards another losing week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$11.70
Prev Close	$11.74
Open	$11.74
Dividend Yield	0.00%
50-Day Moving Average	$11.71
Beta	0.95
Avg. Volume	2.06M
PE Ratio	-5.78

52-Week High	$36.26
52-Week Low	$4.47
Market Capitalization	$1.02B
EPS (Annual)	-$1.87
Price to Book	2.13
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

OLMAOlema Pharmaceuticals Inc

Latest OLMA News